DermTech, Inc. announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (NPV).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.303 USD | -3.93% | -13.43% | -82.69% |
05-14 | DermTech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-14 | Earnings Flash (DMTK) DERMTECH Posts Q1 Revenue $3.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-82.69% | 10.92M | |
-4.22% | 12.45B | |
-0.60% | 8.22B | |
+6.61% | 5.72B | |
-10.21% | 4.11B | |
-60.35% | 2.68B | |
+10.62% | 2.68B | |
-5.50% | 2.37B | |
+16.77% | 2.06B | |
-9.18% | 1.8B |
- Stock Market
- Equities
- DMTK Stock
- News DermTech, Inc.
- DermTech, Inc. Announces Contract with Hawaii Blues Plan for the Foundational Assay of Its Dermtech Melanoma Test